JPX · 4887.T
Sawai Group Holdings Co., Ltd.
¥1,667-¥17 (-1.01%)
Sawai Group Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.9% below the high.
Loading market information…
JPX · 4553.T · JPY
Stock price, dividends, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Towa Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 21.6% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Towa Pharmaceutical Co., Ltd.’s forward annual dividend is ¥80 per share, paid semi-annual. The forward yield is 2.27% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Towa Pharmaceutical Co., Ltd.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of ¥101. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Towa Pharmaceutical Co., Ltd.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Towa Pharmaceutical Co., Ltd., along with its subsidiaries, is actively engaged in the entire pharmaceutical lifecycle within Japan, from researching and developing to manufacturing and marketing prescription medications, active pharmaceutical ingredients, and intermediate compounds. The company's extensive product offerings target critical therapeutic areas, including diabetes, digestive and nervous system disorders, and allergic conditions. Furthermore, their portfolio encompasses vitamins, antibiotics, and oncology treatments. With a comprehensive collection of approximately 700 distinct drug products, Towa Pharmaceutical Co., Ltd. was founded in 1951 and is headquartered in Osaka, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 |
|---|
| May 15, 2025 |
| ¥89-22.2% vs estimate |
| ¥65.86B-5.02% vs estimate |
| Q3 2025 | Feb 13, 2025 | ¥164+184.3% vs estimate | ¥70.33B+0.33% vs estimate |
|---|
| Q2 2025 | Nov 12, 2024 | ¥22-56.61% vs estimate | ¥60.84B+4.89% vs estimate |
|---|
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥1,667-¥17 (-1.01%)
Sawai Group Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 31.9% below the high.
¥3,830+¥30 (+0.79%)
Kaken Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 13.84% below the high.
¥3,285+¥45 (+1.39%)
Mochida Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 17.15% below the high.
¥1,977+¥36 (+1.85%)
Zeria Pharmaceutical Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 18.78% below the high.
¥1,870+¥39 (+2.13%)
Fuji Pharma Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 26.92% below the high.
¥1,323+¥19 (+1.46%)
Daito Pharmaceutical Co.,Ltd.’s quoted price sits in the upper half of its reported 52-week range, 13.02% below the high.
¥2,195-¥23 (-1.04%)
Morishita Jintan Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 8.16% below the high.
